MétaCan
Menu
Back to cohort
Record W2058154005 · doi:10.1186/ar4647

The opportunity and imperative for point-of-care diagnostics in systemic lupus erythematosus

2014· article· en· W2058154005 on OpenAlexafffund
Marvin J. Fritzler

Bibliographic record

VenueArthritis Research & Therapy · 2014
Typearticle
Languageen
FieldMedicine
TopicSystemic Lupus Erythematosus Research
Canadian institutionsUniversity of Calgary
FundersNational Institute of Arthritis and Musculoskeletal and Skin DiseasesNational Institute of Allergy and Infectious DiseasesCanadian Institutes of Health ResearchLupus Research AllianceCentral New York Community FoundationMerck KGaANational Institutes of HealthLupus Foundation of America
KeywordsRheumatologyMedicineIntensive care medicineSystemic lupus erythematosusPoint of careSystemic lupusInternal medicinePathologyDisease

Abstract

fetched live from OpenAlex

The development of point-of-care diagnostics (POCD) is prompted by the global burden of diseases attended by high morbidity and mortality when the diagnosis is delayed. POCD are designed to bring diagnostic tests immediately accessible to the site of patient care. In general terms, these devices are simple to use, economical, have high specificity and have a short turnaround time, enabling rapid clinical decisions. Contemporary POCD devices target blood glucose, coagulation, cardiac markers, infectious diseases, pregnancy and cholesterol testing. Systemic lupus erythematosus (SLE) is a suitable target for POCD because it can present with a variety of rapid-onset and life-threatening features, and is characterized by a number of well-defined disease-specific biomarkers. Clinical scenarios where POCD would benefit the management of SLE include CNS lupus (psychosis, encephalitis, stroke, seizures), transverse myelitis, acute renal failure, pulmonary hemorrhage and pneumonitis, cytopenias (thrombocytopenia, anemia, neutropenia, leukopenia), catastrophic antiphospholipid syndrome, cardiac tamponade and infarction, fetal heart block, mesenteric vasculitis and pancreatitis. In collaboration with Dr Fooke Laboratorien GmbH (Neuss, Germany) we are developing and beta testing a lateral flow POCD that detects anti-dsDNA within 20 minutes after application of 10 μl serum. Twenty preselected SLE sera and age and gender-matched controls were tested. Interpretation of the test results were performed by direct visual observation or by densitometry using a portable lateral flow assay reader. Semi-quantitative results were expressed as relative units. When compared with results of the conventional Crithidia lucilliae assay, the POCD had a sensitivity of 90% and a specificity of 100%. Further testing to establish sensitivity, specificity and receiver operator characteristic in unselected SLE and control sera are underway. Pilot data using this lateral flow POCD were favorable and had similar characteristics as those recently published by N Offermann in the Journal of Immunological Methods . The features of future POCD are based on advanced diagnostic platforms such as lateral flow, novel nanomaterials and microfluidics (lab on a chip), which are miniaturized and portable, have high specificity and design, are multiplexed and high throughput, and are standardized.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.055
metaresearch head score (Gemma)0.129
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.055
Threshold uncertainty score0.293

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0550.129
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0020.001
Science and technology studies0.0020.008
Scholarly communication0.0070.012
Open science0.0020.006
Research integrity0.0060.011
Insufficient payload (model declined to judge)0.0080.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.052
GPT teacher head0.362
Teacher spread0.310 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2014
Admission routes2
Has abstractyes

Explore more

Same venueArthritis Research & TherapySame topicSystemic Lupus Erythematosus ResearchFrench-language works237,207